Qrons (QRON) 10-K 25 Mar 19 2018 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2018	Mar. 22, 2019	Jun. 30, 2018
Document And Entity Information
Entity Registrant Name	Qrons Inc.
Entity Central Index Key	0001689084
Document Type	10-K
Document Period End Date	Dec. 31, 2018
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Is Entity Emerging Growth Company?	true
Elected Not To Use the Extended Transition Period	false
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Public Float			$ 6,955,773
Entity Common Stock, Shares Outstanding		12,942,309
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2018
Entity Shell Company	false

Balance Sheets

Balance Sheets - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Current assets
Cash and cash equivalents	$ 143,862	$ 57,767
Prepaid expenses	51,985	15,812
Total current assets	195,847	73,579
TOTAL ASSETS	195,847	73,579
Current liabilities
Accounts payable and accrued liabilities	23,324	14,141
Accounts payable and accrued liabilities - related party	3,421	1,410
Convertible note - related party, net of debt discount	25,000	6,665
Derivative liabilities	36,827	31,090
Total current liabilities	88,572	53,306
Total liabilities	88,572	53,306
Stockholders' equity
Series A Preferred Shares: $0.001 par value, authorized 10,000; 2,000 shares issued and outstanding	2	2
Common stock, $0.0001 par value: shares authorized 100,000,000; 12,872,309 and 12,404,910 shares issued and outstanding at December 31, 2018 and December 31, 2017, respectively	1,287	1,240
Additional Paid-in Capital	5,629,694	1,611,711
Accumulated deficit	(5,523,708)	(1,592,680)
Total stockholder's equity	107,275	20,273
TOTAL LIABILITIES & STOCKHOLDERS' EQUITY	$ 195,847	$ 73,579

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2018	Dec. 31, 2017
Statement of Financial Position [Abstract]
Series A Preferred Shares, par value	$ 0.001	$ 0.001
Series A Preferred Shares, authorized	10,000	10,000
Series A Preferred Shares, shares issued	2,000	2,000
Series A Preferred Shares, shares outstanding	2,000	2,000
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	12,872,309	12,404,910
Common stock, shares outstanding	12,872,309	12,404,910

Statements of Operations

Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Income Statement [Abstract]
Net sales
Operating expenses:
Research and development expenses	919,706	1,179,777
Professional fees	44,147	22,429
General and administrative expenses	2,941,092	200,939
Total operating expenses	3,904,945	1,403,145
Income (loss) from operations	(3,904,945)	(1,403,145)
Other income (expense)
Interest expense	(20,346)	(14,205)
Change in derivative liabilities	(5,737)	(6,090)
Total Other income (expense)	(26,083)	(20,295)
Net (loss)	$ (3,931,028)	$ (1,423,440)
Net (loss) per common shares (basic and diluted)	$ (0.31)	$ (0.12)
Weighted average shares outstanding Basic and diluted	12,770,845	11,657,791

Statement of Changes In Stockho

Statement of Changes In Stockholders’ Equity - USD ($)	Series A Preferred Shares	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Total
Balance at Dec. 31, 2016	$ 2	$ 1,142	$ 319,468	$ (169,240)	$ 151,372
Balance, shares at Dec. 31, 2016	2,000	11,424,000
Issuance of common stock for private placement		$ 13	31,987		32,000
Issuance of common stock for private placement, shares		128,000
Financing costs associated with S-1			(22,548)		$ (22,548)
Warrants exercised associated with private placement		$ 44	(44)
Warrants exercised associated with private placement, shares		442,960			442,960
Warrants exercised associated with License and Research Funding Agreement		$ 12	335,848		$ 335,860
Warrants exercised associated with License and Research Funding Agreement, shares		119,950
Shares issued for stock awards		$ 29	811,971		812,000
Shares issued for stock awards, shares		290,000
Stock option granted to officers			106,029		106,029
Stock option granted to non-employees			29,000		29,000
Net loss for the year				(1,423,440)	(1,423,440)
Balance at Dec. 31, 2017	$ 2	$ 1,240	1,611,711	(1,592,680)	20,273
Balance, shares at Dec. 31, 2017	2,000	12,404,910
Issuance of common stock for private placement		$ 38	574,962		575,000
Issuance of common stock for private placement, shares		380,684
Warrants exercised associated with private placement
Warrants exercised associated with private placement, shares		1,715
Shares issued for stock awards		$ 1	27,999		28,000
Shares issued for stock awards, shares		10,000
Shares issued for services provided		$ 8	149,992		150,000
Shares issued for services provided, shares		75,000
Stock option granted to officers			2,673,011		2,673,011
Stock option granted to non-employees			152,626		152,626
Stock option granted to employees as research and development costs			439,393		439,393
Net loss for the year				(3,931,028)	(3,931,028)
Balance at Dec. 31, 2018	$ 2	$ 1,287	$ 5,629,694	$ (5,523,708)	$ 107,275
Balance, shares at Dec. 31, 2018	2,000	12,872,009

Statements of Cash Flows

Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Cash Flows From Operating Activities
Net loss	$ (3,931,028)	$ (1,423,440)
Adjustments to reconcile net loss to net cash provided from (used by) operating activities:
Stock options recorded as research and development expense	592,019	812,000
Stock awards recorded as advisory and consulting services	178,000
Shares issued as research and development expense		335,860
Stock options granted and recorded as administrative expenses	2,673,011	135,029
Accretion of debt discount	18,335	13,082
Change in derivative liabilities	5,737	6,090
Changes in operating assets and liabilities:
Prepaid expenses	(36,173)	(15,812)
Accounts payable and accrued liabilities	9,183	13,854
Accounts payable and accrued liabilities, related party	2,011	1,410
Net cash provided (used by) operating activities	(488,905)	(121,927)
Cash Flows From Investing Activities
Net cash provided from (used by) investing activities
Cash Flows From Financing Activities
Proceeds from convertible note		15,000
Proceeds from private placement	575,000	32,000
Financing costs		(22,548)
Net cash provided from financing activities	575,000	24,452
Increase (decrease) in cash and cash equivalents	86,095	(97,475)
Cash at beginning of year	57,767	155,242
Cash at end of year	143,862	57,767
SUPPLEMENTAL DISCLOSURES
Interest paid
Income taxes paid
SUPPLEMENTAL NON-CASH FINANCING ACTIVITIES
Derivative liability associated with debt discount		$ 25,000

Description of Business and Bas

Description of Business and Basis of Presentation	12 Months Ended
	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business and Basis of Presentation	Note 1 – Description of Business and Basis of Presentation Organization and nature of business: Qrons Inc. ("Qrons" or the "Company") was incorporated under the laws of the State of Wyoming on August 22, 2016 under the name BioLabMart Inc. On July 6, 2017, the board of directors and a majority of the Company's shareholders approved an amendment to the Company's Articles of Incorporation to change the name of the Company from "BioLabMart Inc." to "Qrons Inc.". On August 8, 2017, the Company filed Amended Articles of Incorporation with the State of Wyoming to effectuate such name change. The Company's common stock was approved by the Financial Industry Regulatory Authority ("FINRA") for quotation on the OTC pink sheets under the symbol "BLMB" as of July 3, 2017. FINRA announced the Company's name change to Qrons Inc. on its Daily List on August 9, 2017. The new name and symbol change to "QRON" for the OTC Market was effective August 10, 2017. The Company is a p reclinical stage biotechnology company developing advanced stem cell-synthetic hydrogel-based solutions to combat neuronal injuries and achieve a breakthrough in the treatment of traumatic brain injuries ("TBIs"), for both concussions and penetrating injuries, an unmet medical need. We believe that our approach is The Company collaborates treatment that integrates proprietary, engineered mesenchymal stem cells (“MSCs”), synthetic hydrogels, 3D printable implant, smart materials and a novel delivery system. On March 15, 2019, the Company relocated its principal executive office from Miami, Florida to 50 Battery Place, #7T, New York, New York 10280. Ariel Agreements On December 14, 2016, the Company entered into a license and research funding agreement ("License Agreement") with Ariel Scientific Innovations Ltd., formerly known as Ariel University R&D Co., Ltd., a wholly owned subsidiary of Ariel University, based in Ariel, Israel ("Ariel"). Under the terms of the License Agreement, for certain agreed cash consideration, the Company received an exclusive worldwide royalty- bearing license in Ariel patents and know-how to develop and commercialize products based on or incorporating conditioned medium for neuronal tissue regeneration and/or repair, resulting from Ariel's research or technology or the Company's research funding in accordance with milestones set forth in the agreement. In lieu of extending the research financing and research period under the License Agreement beyond the initial 12 months, on December 14, 2017, the Company entered into a 12-month services agreement with Ariel (the "Services Agreement") pursuant to which a team at Ariel under the direction of Prof. Danny Baranes will conduct molecular biology research activities involving the testing of implant materials for the Company. On April 12, 2018, the Services Agreement was amended to provide for additional services as the Company may request. On March 6, 2018, the Company entered into an additional services agreement with Ariel for the services of Professor Gadi Turgeman and his neurobiology research team in their lab. On December 12, 2018, the Company further amended the Services Agreement with Ariel to extend the term thereof for an additional twelve-month period until December 14, 2019. All other terms and conditions of the Services Agreement not amended remain in effect. Dartmouth Agreements On October 17, 2017, the Company entered into an Option Agreement (the "Option Agreement") with the Trustees of Dartmouth College (“Dartmouth”) which provides for, among other things, the grant to the Company of a one-year exclusive option to negotiate a worldwide, royalty bearing, exclusive license with Dartmouth for 3D printable materials in the field of human and animal health. During the option period, the Company agreed to use all commercially reasonable resources to evaluate the intellectual property and provide quarterly milestone reports and a commercialization plan upon exercise of the option. Pursuant to the Option Agreement, the Company agreed to finance the prosecution of patents by Dartmouth to protect its intellectual property. Further, the Option Agreement provides for the payment by the Company of an option fee and certain license fees and royalty payments based upon the Company's product sales, as part of a final negotiated license agreement. The Company exercised its option on March 26, 2018 to negotiate definitive license terms, as it continues further evaluation and research. On July 12, 2018, the Company entered into a one-year sponsored research agreement (the "Sponsored Research Agreement"), with Dartmouth pursuant to which the Company will support and fund the cost of research conducted by Dartmouth of mutual interest to the parties in accordance with the terms of the Sponsored Research Agreement. Intellectual property invented or developed solely by a party shall be owned by such party and intellectual property jointly invented or developed shall be jointly owned. Dartmouth shall retain an irrevocable worldwide right to use intellectual property owned by it resulting from its research under the Sponsored Research Agreement on a non-exclusive royalty-free basis for research and education purposes. The Sponsored Research Agreement may be terminated earlier than one year upon written agreement of the parties, a material breach which is not cured within 30 days of notice thereof, if Professor Ke no longer conducts the research under the Sponsored Research Agreement and a successor acceptable to both parties is not available, or in the event of an unauthorized assignment of the Company's rights and obligations under the Sponsored Research Agreement.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2 – Summary of Significant Accounting Policies Financial Statement Presentation: Fiscal year end: Use of Estimates: Cash Equivalents: Research and Development Costs: esearch and development costs were $1,179,777 for the year ended December 31, 2017, inclusive of stock-based compensation cost. Advertising and Marketing Costs: The Company incurred $56,879 and $28,481 in advertising and marketing costs during the years ended December 31, 2018 and 2017, respectively. Related parties: Stock-Based Compensation and Other Share-Based Payments: Stock Plan Fair Value of Financial Instruments FASB ASC 820, Fair Value Measurements and Disclosures, defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. FASB ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. FASB ASC 820 describes three levels of inputs that may be used to measure fair value: Level 1 Level 2 Level 3 If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level of input that is significant to the fair value measurement of the instrument. The following table provides a summary of the fair value of the Company’s derivative liabilities as of December 31, 2018 and December 31, 2017: Fair value measurements on a recurring basis Level 1 Level 2 Level 3 As of December 31, 2018: Liabilities Derivative liabilities $ - $ - $ 36,827 As of December 31, 2017: Liabilities Derivative liabilities $ - $ - $ 31,090 Warrants: "Derivatives and Hedging – Contracts in Entity's Own Equity" Income taxes: Basic and Diluted Loss Per Share Potential common stock consists of the incremental common stock issuable upon the exercise of common stock warrants (using the if-converted method), convertible notes, classes of shares with conversion features, and stock awards and stock options. The computation of basic loss per share for the years ended December 31, 2018 and 2017 excludes potentially dilutive securities of underlying share purchase warrants, convertible notes, stock options and preferred shares, because their inclusion would be antidilutive. As a result, the computations of net loss per share for each period presented is the same for both basic and fully diluted. The table below reflects the potentially dilutive securities at each reporting period which have been excluded from the computation of diluted net loss per share: December 31, 2018 December 31, 2017 Stock purchase warrants 52,000 54,000 Research Warrants at 3% of issued and outstanding shares 386,170 372,147 Convertible Notes 27,864 18,864 Series A Preferred shares 700 700 Stock options vested 1,486,670 13,334 Stock options not yet vested 128,330 656,666 Stock award not yet vested - 290,000 Total 2,081,734 1,405,711 New Accounting Pronouncements: In June 2018, an accounting update was issued by FASB to simplify the accounting for nonemployee share-based payment transactions resulting from expanding the scope of ASC Topic 718, Compensation-Stock Compensation ASC Topic 718 ASC Topic 718 ASC Topic 718 ASC Topic 606, Revenue from Contracts with Customers ASC Topic 606

Going Concern

Going Concern	12 Months Ended
	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	Note 3 – Going Concern The Company has experienced net losses to date, and it has not generated revenue from operations. While the Company raised proceeds during 2018, it does not believe its resources will be sufficient to meet its operating and capital needs beyond the second quarter of 2019. The Company expects it will require additional capital to fully implement the scope of its proposed business operations, which raises substantial doubt about its ability to continue as a going concern. The Company will have to continue to rely on equity and debt financing. There can be no assurance that financing, whether debt or equity, will always be available to the Company in the amount required at any particular time or for any particular period or, if available, that it can be obtained on favorable terms. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or amount and classification of liabilities that might cause results from this uncertainty.

Convertible Note - Related Part

Convertible Note - Related Party and Derivative Liabilities	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Convertible Note - Related Party and Derivative Liabilities	Note 4 – Convertible Note – Related Party and Derivative Liabilities On September 1, 2016, the Company entered into a convertible debenture agreement with CubeSquare, LLC ("CubeSquare"), of which its Chief Executive Officer is the managing partner and its President is a 25% owner. The Company received proceeds of $10,000 during fiscal 2016 ("Note 1"). The note bears interest at 8% per annum and was due on September 1, 2017. Interest accrues from September 1, 2016 and is payable on maturity. Interest is payable, at the lender's option, in cash or common stock. Any portion of the loan and unpaid interest is convertible at any time at the option of the lender into shares of common stock of the Company at a conversion price of the greater of (i) $0.0625 per share if the Company's shares are not trading on a public market and; (ii) in the event the Company's shares are listed for trading on a public market, the conversion price shall be equal to a 50% discount to the average of the five lowest trading prices during the previous twenty trading days prior to the date of the notice of conversion from the lender. On September 28, 2017 the Company and CubeSquare amended Note 1 to extend the maturity date from September 1, 2017 to September 1, 2018 and on September 9, 2018, the Company further amended Note 1 to extend the maturity date to September 1, 2019, under the same terms and conditions. On September 27, 2017, the Company entered into a second convertible debenture agreement with CubeSquare under which the Company received proceeds of $15,000 (Note 2). Note 2 bears interest at 8% per annum and is due on September 27, 2018. Interest shall accrue from September 27, 2017 and shall be payable on maturity. Any portion of the principal and unpaid interest under the note is convertible at any time at the option of CubeSquare into shares of common stock of the Company at a conversion price equal to a 50% discount to the average of the five lowest trading prices during the previous twenty trading days prior to the date of the notice of conversion from CubeSquare. On September 9, 2018, Note 2 was amended to extend the maturity date until September 27, 2019. The Company analyzed the amendment to Note 1 and Note 2 under and concluded that these two convertible debentures We estimated the fair value of the derivative on the inception dates, and subsequently, using the Black-Scholes valuation technique, adjusted for the effect of dilution, because that technique embodies all of the assumptions (including, volatility, expected terms, and risk-free rates) that are necessary to fair value complex derivate instruments. The carrying value of these convertible notes is as follows: December 31, 2018 December 31, 2017 Face value of certain convertible notes $ 25,000 $ 25,000 Less: unamortized discount - (18,335 ) Carrying value $ 25,000 $ 6,665 Amortization of the discount over the years ended December 31, 2018 and 2017 totaled $18,335 and $13,082, respectively, which amounts have been recorded as interest expense. As a result of the application of ASC No. 815 in the periods ended December 31, 2018 and December 31, 2017 the fair value of the conversion feature is summarized as follows: Balance at December 31, 2016 $ - Derivative addition associated with convertible notes 25,000 Loss on change in fair value 6,090 Balance at December 31, 2017 31,090 Derivative addition associated with convertible notes - Change in fair value 5,737 Balance at December 31, 2018 $ 36,827 The fair value at the commitment and re-measurement dates for the Company's derivative liabilities were based upon the following management assumptions as of December 31, 2018 and commitment date: Commitment Date December 31, 2018 December 31, 2017 Expected dividends 0 0 0 Expected volatility 101% ~103% 64% ~ 65% 110% ~ 115% Expected term 0.92 ~ 1 year 0.67 ~0.74 year 0.67 ~0.74 year Risk free interest rate 1.33% 2.60% 1.53% ~ 1.65%

License and Research Funding Ag

License and Research Funding Agreements	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
License and Research Funding Agreements	Note 5 – License and Research Funding Agreements On December 14, 2016, the Company entered into the License Agreement with Ariel under which the Company paid Ariel $100,000 to fund research for 12 months (with an option to extend such research financing and research period). In consideration therefore, the Company received an exclusive worldwide royalty-bearing license in Ariel patents and know-how to develop and commercialize products based on or incorporating coral-based conditioned medium for neuronal tissue regeneration and/or repair, resulting from Ariel's research or technology or the Company's research funding in accordance with milestones set forth in the Agreement. In addition, upon the occurrence of an Exit Event (as defined in the License Agreement) of the Company or of any affiliate commercializing the products, the Company is obligated to issue to Ariel an immediately exercisable warrant for that number of shares equal to 4% of the issued and outstanding shares of the Company at the time of issuance. The Company and Ariel entered into Addendum #1 to the License Agreement, effective December 13, 2017 (the "Addendum") pursuant to which Ariel was permitted to exercise a portion of the warrant granted pursuant to the License Agreement. On December 13, 2017, the Company issued 119,950 shares of common stock to Ariel, representing 1% of the issued and outstanding shares of the Company on such date, and valued at $335,860. The right to the balance of the shares subject to the warrant remains subject to the terms of the License Agreement and the occurrence of an Exit Event (as described in the License Agreement). In addition, the Addendum provides that Ariel may not request a demand registration until the balance of the shares subject to the warrant is exercised. In addition to the other payments, the Company will pay Ariel upon the occurrence of the following milestone events, additional payments which shall be due within 6 months of completion of the milestone: - Upon successful clinical FDA Phase II completion - $130,000; and - Upon successful clinical FDA Phase III completion - $390,000 Upon successful development and commercialization and in recognition of the rights and licenses granted to the Company pursuant to the License Agreement, the Company will be subject to certain royalty payments as specified in the License Agreement. During the year ended December 31, 2017, the Company incurred total research and development costs of $1,179,777, which amount includes the aforementioned value of 119,950 shares of common stock at In lieu of extending the research financing and research period under the License Agreement with Ariel beyond the initial 12 months, on December 14, 2017, the Company entered into the Services Agreement pursuant to which a team at Ariel University under the direction of Professor Danny Baranes will conduct molecular biology research activities involving the testing of scaffold materials for the Company. As compensation for such services, the Company paid Ariel (i) $17,250 on December 19, 2017 and an additional $17,250 on April 26, 2018. On April 12, 2018, the Services Agreement was amended to provide for the payment by the Company of an additional monthly fee, commencing March 2018, of up to 8,000 Israeli shekels as compensation for additional costs which the Company may request. On March 6, 2018, the Company entered into an additional service agreement with Ariel for the services of Professor Gadi Turgeman and his neurobiology research team in their lab pursuant to which the Company paid Ariel $20,580 on each of March 19, 2018 and August 22, 2018. The Services Agreement and first amendment thereto, dated April 12, 2018 were previously filed with the SEC with the Company's Current Reports on Form 8-K on December 15, 2017 and April 16, 2018, respectively. On December 12, 2018, the Company further amended the Services Agreement (the "Second Amendment") with Ariel to extend the term thereof for an additional twelve-month period until December 14, 2019. The Second Amendment also provides that the Company pay Ariel $17,250 within 30 days of the date of the Amendment and an additional $17,250 on or before May 1, 2019. All other terms and conditions of the Services Agreement not amended remain in effect. On July 12, 2018, the Company entered into the Sponsored Research Agreement with Dartmouth pursuant to which the Company will support and fund the cost of research conducted by Dartmouth of mutual interest to the parties in accordance with the Agreement. Intellectual property invented or developed solely by a party shall be owned by such party and intellectual property jointly invented or developed shall be jointly owned. Dartmouth shall retain an irrevocable worldwide right to use intellectual property owned by it resulting from its research under the Agreement on a non-exclusive royalty-free basis for research and education purposes. The Agreement may be terminated earlier than one year upon written agreement of the parties, a material breach which is not cured within 30 days of notice thereof, if Professor Ke no longer conducts the research under the Agreement and a successor acceptable to both parties is not available, or in the event of an unauthorized assignment of the Company's rights and obligations under the Agreement.

Commitments

Commitments	12 Months Ended
	Dec. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Commitments	Note 6 – Commitments (1) Service Agreement with Ariel Scientific Innovations Ltd On December 14, 2017, the Company entered into the Services Agreement pursuant to which a team at Ariel under the direction of Prof. Danny Baranes will conduct molecular biology research activities involving the testing of implant materials for the Company. As compensation for the services provided, the Company will pay Ariel (i) $17,250 within five business days of the execution of the Services Agreement, and (ii) $17,250 by May 1, 2018. The Services Agreement may be terminated by the non-breaching party upon a material breach that is not cured within 30 days or by the Company upon thirty days' prior written notice to Ariel. Ariel must keep confidential information of the Company confidential for five years after the term of the Services Agreement. During the year ended December 31, 2017, $17,250 was paid and on April 26, 2018, the remaining installment of $17,250 was paid. On April 12, 2018, the Services Agreement was amended to provide for the payment by the Company of an additional monthly fee, commencing March 2018, of up to $2,130 (8,000 Israeli shekels) as compensation for additional costs which the Company may request. During the year ended December 31, 2018, the Company paid $16,935 for these additional costs. On December 12, 2018, the Company further amended the Services Agreement with Ariel (the "Second Amendment") to extend the term thereof for an additional twelve-month period until December 14, 2019. The Second Amendment also provides that the Company pay Ariel $17,250 within 30 days of the date of the Amendment and an additional $17,250 on or before May 1, 2019. All other terms and conditions of the Services Agreement not amended remain in effect. During the year ended December 31, 2018 and December 31, 2017, $33,781 and $1,438 were expensed, respectively, and the remaining $16,531 (December 31, 2017 - $15,812), which amount is reflected on the Company's balance sheets as prepaid expenses, will be expensed in a subsequent period. (2) Service Agreement with Ariel - Dr. Gadi Turgeman On March 6, 2018, the Company entered into a service agreement for the services of Professor Gadi Turgeman and his neurobiology research team in their lab. As compensation for the services provided, the Company paid Ariel $20,580 on each of March 19, 2018 and August 22, 2018. The Services Agreement may be terminated by the non-breaching party upon a material breach that is not cured within 30 days or by the Company upon thirty days' prior written notice to Ariel. Ariel must keep confidential information of the Company confidential for six years after the term of the Services Agreement. During the year ended December 31, 2018, $41,160 was paid and recorded as prepaid expenses, of which $34,300 was expensed in the year ended December 31, 2018, and the remaining $6,860 will be expensed in a subsequent period. (3) Science Advisory Board Member Consulting Agreements (the "Agreements") As part of its ongoing program of research and development, the Company has retained distinguished scientists and other qualified individuals to advise the Company with respect to its technology and business strategy and to assist it in the research, development and analysis of the Company's technology and products. In furtherance thereof, the Company has retained certain Advisors as members of its Scientific Advisory Board as described below, and the Company and Advisors have entered into agreements with the following terms and conditions: - Scientific Advisory Board and Consulting Services - Advisor shall provide general consulting services to Company (the "Services") as a member of its Scientific Advisory Board ("SAB"). As a member of the SAB, Advisor agrees to provide the Services as follows: (a) attending meetings of the Company's SAB; (b) performing the duties of a SAB member at such meetings, as established from time to time by the mutual agreement of the Company and the SAB members, including without limitation meeting with Company employees, consultants and other SAB members, reviewing goals of the Company and assisting in developing strategies for achieving such goals, and providing advice, support, theories, techniques and improvements in the Company's scientific research and product development activities; and (c) providing consulting services to Company at its request, including a reasonable amount of informal consultation over the telephone or otherwise as requested by Company. Advisor's consultation with Company will involve services as scientific, technical and business advisor to the Company and its management with respect to neuronal injuries and neuro degenerative diseases. - SAB Consulting Compensation - the Company shall grant to Advisor the option to purchase certain number of shares of the common stock of the Company as per the stock option award grant. The options are subject to terms and provisions of the Company's 2016 Stock Option and Stock Award Plan. On November 15, 2017, the Company entered into Agreements with three Advisors under the terms of which two Advisors are granted an option to purchase 20,000 shares of common stock and one Advisor was granted an option to purchase 30,000 shares of common stock under the 2016 Stock Option and Award Plan subject to certain vesting terms. On April 16, 2018, the Company entered into a one-year advisory board member consulting agreement with an assistant Professor of Chemistry at Dartmouth College to serve on the Company's Scientific Advisory Board. In consideration for serving on the Scientific Advisory Board, the Company granted an option to purchase 30,000 shares of its common stock under certain vesting terms to the assistant Professor. On August 15, 2018, the Company entered into an Agreement with an Advisor under the terms of which the Company granted an option to purchase 20,000 shares of common stock under the 2016 Stock Option and Award Plan subject to certain vesting terms. (4) Business Advisory Board Agreement On January 23, 2018, the Company entered into a one-year advisory board member consulting agreement with Pavel Hilman, the controlling shareholder of Conventus Holdings SA, a BVI corporation ("Conventus"), under which Mr. Hilman will serve on the Company's Advisory Board as a business advisor. The Advisory Board Agreement will automatically renew for up to two additional one-year periods, unless earlier terminated by either party upon 30 days' prior written notice to the other party. In consideration for serving on the Advisory Board, the Company awarded 10,000 shares of its common stock to Mr. Hilman under its 2016 Stock Option and Stock Award Plan. (5) Investor Relations Agreement On April 23, 2018, the Company entered into a six-month investor relations agreement with an investor relations firm for a monthly consulting fee of $5,000 and the issuance of 75,000 shares of common stock payable on signing the agreement. On June 23, 2018, the Company gave notice of rescission of the agreement to such firm and requested the return of the consulting fee paid and the 75,000 shares of common stock. As a result, the Company has not recorded any fees for services rendered past June 23, 2018. A total of $10,000 representing April 2018 and May 2018 monthly consulting fees is reflected in the statement of operations and a total of $150,000, the fair market value of the issued shares, was expensed on issue. As at the date of this report no fees or shares have been recovered. (6) Sponsored Research Agreement On July 12, 2018, the Company entered into the Sponsored Research Agreement with Dartmouth pursuant to which the Company will support and fund the cost of research conducted by Dartmouth of mutual interest to the parties in accordance with the Agreement. Intellectual property invented or developed solely by a party shall be owned by such party and intellectual property jointly invented or developed shall be jointly owned. Dartmouth shall retain an irrevocable worldwide right to use intellectual property owned by it resulting from its research under the Agreement on a non-exclusive royalty-free basis for research and education purposes. The Company funded $36,293 on August 20, 2018 and funded an additional $18,147 on December 17, 2018 and is required to fund an additional $18,146 by June 1, 2019. The Agreement may be terminated earlier than one year upon written agreement of the parties, a material breach which is not cured within 30 days of notice thereof, if Professor Ke no longer conducts the research under the Agreement and a successor acceptable to both parties is not available, or in the event of an unauthorized assignment of the Company's rights and obligations under the Agreement. During the year ended December 31, 2018, $54,440 was paid and recorded as prepaid expenses, of which $27,220 was expensed in the year ended December 31, 2018, and the remaining $27,220 will be expensed in a subsequent period.

Stock Plan

Stock Plan	12 Months Ended
	Dec. 31, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock Plan	Note 7 – Stock Plan 2016 Stock Option and Stock Award On December 14, 2016, the Board adopted the Company's 2016 Stock Option and Stock Award Plan (the "Plan"). The Plan provides for the award of stock options (incentive and non-qualified), stock awards and stock appreciation rights to officers, directors, employees and consultants who provide services to the Company. The terms of awards under the Plan are made by the Administrator of the Plan appointed by the Company's Board of Directors (the "Board"), or in the absence of an Administrator, by the Board. The Company has reserved 10 million shares for issuance under the Plan. Stock Awards: On December 14, 2016, the Board awarded to each of Prof. Danny Baranes, a Science Advisor and Dr. Liat Hammer, a former Science Advisor, a total of 440,000 shares of common stock of which 150,000 shares vested on December 14, 2016 and 145,000 shares vested on December 14, 2017. The balance of 145,000 shares did not vest as the nature of such services in such capacities were no longer provided to the Company. The value of the vested awards had been recorded as research and development expenses in the respective periods. A total of 290,000 stock awards did not vest during the fourth quarter of fiscal 2018. On January 23, 2018, the Company awarded 10,000 shares of its common stock to Mr. Hilman under its 2016 Stock Option and Stock Award Plan, which shares were fully vested and recorded as advisory services on issuance. For the years ended December 31, 2018 2017 Number of shares vested in period 10,000 290,000 Fair market value per share $ 2.80 $ 2.80 Stock based compensation recognized $ 28,000 $ 812,000 Stock Options: (a) Stock Options granted to Science Advisors: On November 15, 2017, under the 2016 Stock Option and Award Plan, the Board awarded two of its Science Advisors the following three-year stock options: (i) an immediately exercisable option to purchase 6,667 shares of common stock at an exercise price of $2.00 per share, (ii) an option to purchase 6,667 shares of common stock exercisable on November 15, 2018 at an exercise price of $2.00 per share and (iii) an option to purchase 6,666 shares of common stock exercisable on November 15, 2019 at an exercise price of $2.00 per share, provided the advisors are still providing services to the Company. On November 15, 2017, under the 2016 Stock Option and Award Plan, the Board awarded a Science Advisor, the following three-year stock options: (i) an option to purchase 15,000 shares of common stock, exercisable on November 15, 2018 at an exercise price of $0.40 per share and (ii) an option to purchase 15,000 shares of common stock exercisable on November 15, 2019 at an exercise price of $0.40 per share, provided the advisor is still providing services to the Company. On April 16, 2018, under the 2016 Stock Option and Award Plan, the Board awarded a Science Advisor, the following three-year stock options: (i) an option to purchase 10,000 shares of common stock, exercisable on April 16, 2018 at an exercise price of $2.00 per share (ii) an option to purchase 10,000 shares of common stock exercisable on April 16, 2019 at an exercise price of $2.00 per share, and (iii) an option to purchase 10,000 shares of common stock exercisable on April 16, 2020 at an exercise price of $2.00 per share, provided the advisor is still providing services to the Company. On August 15, 2018, under the 2016 Stock Option and Award Plan, the Board granted a Science Advisor an option to purchase an aggregate of 20,000 shares of common stock at an exercise price of $2.00 per share. The option vests as to 6,667 shares on each of August 15, 2018 and August 15, 2019 and as to 6,666 shares on August 15, 2020 and remains exercisable as to each such installment for three years from the date of vesting. Stock Options: (continued) (b) Stock Options granted Employees: On December 10, 2018, under the 2016 Stock Option and Award Plan, the Board granted an immediately exercisable five-year option purchase an aggregate of 145,000 shares of common stock at an exercise price of $2.00 per share to as a “replacement award” for the same number of shares which did not vest as described in Note 7-Stock Awards. Applying the On December 10, 2018, under the 2016 Stock Option and Award Plan, the Board awarded an employee the following three-year stock options: (i) an option to purchase 33,334 shares of common stock, exercisable on December 10, 2018 at an exercise price of $2.00 per share (ii) an option to purchase 33,333 shares of common stock exercisable on December 10, 2019 at an exercise price of $2.00 per share, and (iii) an option to purchase 33,333 shares of common stock exercisable on December 10, 2020 at an exercise price of $2.00 per share, provided the advisor is still providing services to the Company. During the year ended December 31, 2018 and December 31, 2017, total recognized compensation in respect of the above stock option compensation was $592,019 and $29,000, respectively, which amount has been allocated as advisory services as part of general and administrative expenses. As of December 31, 2018, total unrecognized compensation remaining to be recognized in future periods totaled $198,088. (c) Stock Options granted to Officers: On December 4, 2017, the Board granted five-year options to each of its two officers . The options have an exercise price of $2.00 and vest and become exercisable on December 4, 2018. On December 10, 2018, the Board granted five-year options to each of its two officers . The options have an exercise price of $2.00 and are immediately exercisable. During the year ended December 31, 2018 and December 31, 2017, total recognized compensation of $2,673,011 and $106,029, respectively, were recorded as general and administrative expenses. As of December 31, 2018, total unrecognized compensation remaining to be recognized in future periods totaled $0. The fair value of each option award above is estimated on the date of grant using the Black-Scholes option-pricing model with the following assumptions at the measurement date(s): Measurement date Dividend yield 0% Expected volatility 114.69 ~ 126.34% Risk-free interest rate 1.79% ~ 2.68% Expected life (years) 3 ~ 5 Stock Price $ 2.00 ~ 2.80 Exercise Price $ 0.40 ~ 2.00 A summary of the activity for the Company's stock options for the years ended December 31, 2018 and 2017, is as follows: December 31, 2018 December 31, 2017 Weighted Average Weighted Average Shares Exercise Price Shares Exercise Price Outstanding, beginning of period 670,000 $ 1.93 - $ - Granted 945,000 $ 2.00 670,000 $ 1.93 Exercised - $ - - $ - Canceled - $ - - $ - Outstanding, end of period 1,615,000 $ 1.97 670,000 $ 1.93 Options exercisable, end of period 1,486,670 $ 1.98 13,334 $ 2.00 Options expected to vest, end of period 128,330 $ 1.81 656,666 $ 1.89 Weighted average fair value of options granted $ 2.19 $ 2.36

Capital Stock

Capital Stock	12 Months Ended
	Dec. 31, 2018
Equity [Abstract]
Capital Stock	Note 8 – Capital Stock Authorized: The Company has authorized 100,000,000 shares of common stock, par value $0.0001 and 10,000 shares of preferred stock which is designated as Series A Preferred Stock, par value $0.001. Series A Preferred Stock: The Series A Preferred Stock is redeemable at the option of the Company at any time, in whole or in part, upon 10 trading days prior notice, at a price of $1.00 per share plus 4% per annum from the date of issuance (the "Stated Value"). The holders of the Series A Preferred Stock are entitled to a liquidation preference equal to the Stated Value, prior to the holders of other preferred stock or common stock. The holders of the Series A Preferred Stock have the right to convert such stock into common stock at a conversion rate equal to the Stated Value as of the conversion date divided by the average closing price of the common stock for the five previous trading days. The Company is required to reserve sufficient number of shares for the conversion of the Series A Preferred Stock. The holders of Class A Preferred Stock shall vote together as a single class with the holders of the Company's common stock and the holders of any other class or series of shares entitled to vote with the common stock, with the holders of Class A Preferred Stock being entitled to 66 2/3% of the total votes on There was a total of 2,000 shares of Series A Preferred Stock issued and outstanding as of December 31, 2018 and December 31, 2017. Common Stock Common Stock issuances during the year ended December 31, 2018 During the year ended December 31, 2018, the Company sold an aggregate of 380,684 shares of its common stock to investors and received aggregate proceeds of $575,000 pursuant to subscription agreements in private offerings. The proceeds will be used for research and general corporate purposes. On January 23, 2018, During the year ended December 31, 2018, the Company shares of common stock On April 23, 2018, the Company issued 75,000 shares of its common stock pursuant to an investor relations services agreement which was rescinded on June 23, 2018 (Note 6(5)). The shares were valued at the fair market value on the date of issuance for a total of $150,000, or $2.00 per share. Common Stock issuances during the year ended December 31, 2017 On December 13, 2017, 119,950 shares were issued to Ariel upon the exercise of a warrant pursuant to the License Agreement (Note 5 – License and Research Funding Agreement). These shares were valued at $335,860 or $2.80 per share, based on fair market value, and the associated cost was recorded as research and development expenses. On December 14, 2017, the Company issued 290,000 shares to two Scientific Advisors as a stock award, During the year ended December 31, 2017, the Company sold an aggregate of 128,000 shares of common stock to investors and received aggregate proceeds of $32,000 in private offerings. The proceeds of the offering will be used for research and general corporate purposes. During the year ended December 31, 2017 the Company shares of common stock Share Purchase Warrants In accordance with authoritative accounting guidance, the fair value of the aforementioned warrants was calculated using the Black-Scholes option-pricing model with the following assumptions at the measurement date(s): Measurement date Dividend yield 0% Expected volatility 97.90~119.33% Risk-free interest rate 1.47~1.60% Expected life (years) 2.71~2.92 Stock Price $ 0.25 Exercise Price $ 0.40 As of December 31, 2018, and December 31, 2017, the following common stock purchase warrants were outstanding: Warrants (1) Weighted Average Exercise Price Outstanding – December 31, 2016 502,000 $ 0.40 Granted 64,000 0.40 Forfeited/Canceled - - Exercised 512,000 (2) 0.40 Outstanding – December 31, 2017 54,000 0.40 Granted - - Forfeited/Canceled - - Exercised 2,000 (3) 0.40 Outstanding – December 31, 2018 52,000 $ 0.40 (1) Each two shares of common stock purchased under the private placement provides for one warrant to acquire an additional share of common stock together with the payment of $0.40. (2) During the year ended December 31, 2017, investors exercised warrants to purchase an aggregate of 512,000 shares of common stock and received 442,960 underlying shares for exercises on a cashless basis. (3) During the year ended December 31, 2018, investors exercised warrants to purchase an aggregate of 2,000 shares of common stock and received 1,715 shares for exercises on a cashless basis.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Income Taxes	Note 9 – Income Taxes On December 22, 2017, the 2017 Tax Cuts and Jobs Act (the “Tax Act”) was enacted including a one-time mandatory transition tax on accumulated foreign earnings and a reduction of the corporate income tax rate to 21% effective January 1, 2018., The Company is required to recognize the effect of the tax law changes in the period of enactment, such as determining the transition tax, remeasuring its U.S. deferred tax assets and liabilities as well as reassessing the net realizability of its deferred tax assets and liabilities. The Company has remeasured its U.S. deferred tax assets at a statutory income tax rate of 21% during years ended December 31, 2017 and December 31, 2018 The income tax expense (benefit) consisted of the following for the years ended December 31, 2018 and December 31, 2017: December 31, 2018 December 31, 2017 Total current $ - $ - Total deferred - - $ - $ - Deferred income taxes reflect the net tax effects of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The following is a reconciliation of the expected statutory federal income tax and state income tax provisions to the actual income tax benefit for the years ended December 31, 2018 and December 31, 2017: December 31, 2018 December 31, 2017 Expected benefit at federal statutory rate $ 825,500 298,900 Non-deductible expenses (724,200 ) (198,900 ) Change in valuation allowance (101,300 ) (100,000 ) $ - $ - The Company had deferred income tax assets as of December 31, 2018 and 2017 as follows: December 31, 2018 December 31, 2017 Loss carryforwards $ 1,137,380 $ 333,880 Less – stock based compensation (933,600 ) (210,600 ) Less – derivative liabilities (2,480 ) (1,280 ) Change in tax effected rates - (22,000 ) Less - valuation allowance (201,300 ) (100,000 ) Total net deferred tax assets $ - $ - Tax years from inception to the year ended December 31, 2018 have been filed and are open for examination by the taxing authorities. The Company recognizes interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses. No such interest or penalties were recognized during the periods presented above. The Company had no accruals for interest and penalties at December 31, 2018. The Company's utilization of any net operating loss carry-forward may be unlikely as a result of its intended activities.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2018
Subsequent Events [Abstract]
Subsequent Events	Note 10 – Subsequent Events On January 28, 2019, the Company issued 30,000 shares of common stock to Pavel Hilman for his continuing service on the Company’s Board of Advisors. On February 25, 2019, the Company sold an aggregate of 40,000 shares of its common stock to two investors and received aggregate proceeds of $40,000 pursuant to subscription agreements in private offerings. The proceeds will be used for research and general corporate purposes. On March 15, 2019 the Company relocated its principal executive office from Miami, Florida to 50 Battery Place, #7T, New York, New York 10280. Jonah Meer, the Company’s Chief Executive Officer and a director, provides the use of this office space at no cost.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Financial Statement Presentation	Financial Statement Presentation:
Fiscal year end	Fiscal year end:
Use of Estimates	Use of Estimates:
Cash Equivalents	Cash Equivalents:
Research and Development Costs	Research and Development Costs: esearch and development costs were $1,179,777 for the year ended December 31, 2017, inclusive of stock-based compensation cost.
Advertising and Marketing Costs	Advertising and Marketing Costs: The Company incurred $56,879 and $28,481 in advertising and marketing costs during the years ended December 31, 2018 and 2017, respectively.
Related parties	Related parties:
Stock-Based Compensation and Other Share-Based Payments	Stock-Based Compensation and Other Share-Based Payments: Stock Plan
Fair Value of Financial Instruments	Fair Value of Financial Instruments FASB ASC 820, Fair Value Measurements and Disclosures, defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. FASB ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. FASB ASC 820 describes three levels of inputs that may be used to measure fair value: Level 1 Level 2 Level 3 If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level of input that is significant to the fair value measurement of the instrument. The following table provides a summary of the fair value of the Company’s derivative liabilities as of December 31, 2018 and December 31, 2017: Fair value measurements on a recurring basis Level 1 Level 2 Level 3 As of December 31, 2018: Liabilities Derivative liabilities $ - $ - $ 36,827 As of December 31, 2017: Liabilities Derivative liabilities $ - $ - $ 31,090
Warrants	Warrants: "Derivatives and Hedging – Contracts in Entity's Own Equity"
Income taxes	Income taxes:
Basic and Diluted Loss Per Share	Basic and Diluted Loss Per Share Potential common stock consists of the incremental common stock issuable upon the exercise of common stock warrants (using the if-converted method), convertible notes, classes of shares with conversion features, and stock awards and stock options. The computation of basic loss per share for the years ended December 31, 2018 and 2017 excludes potentially dilutive securities of underlying share purchase warrants, convertible notes, stock options and preferred shares, because their inclusion would be antidilutive. As a result, the computations of net loss per share for each period presented is the same for both basic and fully diluted. The table below reflects the potentially dilutive securities at each reporting period which have been excluded from the computation of diluted net loss per share: December 31, 2018 December 31, 2017 Stock purchase warrants 52,000 54,000 Research Warrants at 3% of issued and outstanding shares 386,170 372,147 Convertible Notes 27,864 18,864 Series A Preferred shares 700 700 Stock options vested 1,486,670 13,334 Stock options not yet vested 128,330 656,666 Stock award not yet vested - 290,000 Total 2,081,734 1,405,711
New Accounting Pronouncements	New Accounting Pronouncements: In June 2018, an accounting update was issued by FASB to simplify the accounting for nonemployee share-based payment transactions resulting from expanding the scope of ASC Topic 718, Compensation-Stock Compensation ASC Topic 718 ASC Topic 718 ASC Topic 718 ASC Topic 606, Revenue from Contracts with Customers ASC Topic 606

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Summary of the fair value of derivative liabilities	Fair value measurements on a recurring basis Level 1 Level 2 Level 3 As of December 31, 2018: Liabilities Derivative liabilities $ - $ - $ 36,827 As of December 31, 2017: Liabilities Derivative liabilities $ - $ - $ 31,090
Schedule of potentially dilutive securities	December 31, 2018 December 31, 2017 Stock purchase warrants 52,000 54,000 Research Warrants at 3% of issued and outstanding shares 386,170 372,147 Convertible Notes 27,864 18,864 Series A Preferred shares 700 700 Stock options vested 1,486,670 13,334 Stock options not yet vested 128,330 656,666 Stock award not yet vested - 290,000 Total 2,081,734 1,405,711

Convertible Note - Related Pa_2

Convertible Note - Related Party and Derivative Liabilities (Tables)	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Schedule of convertible notes	December 31, 2018 December 31, 2017 Face value of certain convertible notes $ 25,000 $ 25,000 Less: unamortized discount - (18,335 ) Carrying value $ 25,000 $ 6,665
Schedule of fair value of conversion feature	Balance at December 31, 2016 $ - Derivative addition associated with convertible notes 25,000 Loss on change in fair value 6,090 Balance at December 31, 2017 31,090 Derivative addition associated with convertible notes - Change in fair value 5,737 Balance at December 31, 2018 $ 36,827
Schedule of fair value at commitment and re-measurement dates derivative liabilities	Commitment Date December 31, 2018 December 31, 2017 Expected dividends 0 0 0 Expected volatility 101% ~103% 64% ~ 65% 110% ~ 115% Expected term 0.92 ~ 1 year 0.67 ~0.74 year 0.67 ~0.74 year Risk free interest rate 1.33% 2.60% 1.53% ~ 1.65%

Stock Plan (Tables)

Stock Plan (Tables)	12 Months Ended
	Dec. 31, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of stock award	For the years ended December 31, 2018 2017 Number of shares vested in period 10,000 290,000 Fair market value per share $ 2.80 $ 2.80 Stock based compensation recognized $ 28,000 $ 812,000
Schedule of fair value options assumptions	Measurement date Dividend yield 0% Expected volatility 114.69 ~ 126.34% Risk-free interest rate 1.79% ~ 2.68% Expected life (years) 3 ~ 5 Stock Price $ 2.00 ~ 2.80 Exercise Price $ 0.40 ~ 2.00
Schedule of stock options	December 31, 2018 December 31, 2017 Weighted Average Weighted Average Shares Exercise Price Shares Exercise Price Outstanding, beginning of period 670,000 $ 1.93 - $ - Granted 945,000 $ 2.00 670,000 $ 1.93 Exercised - $ - - $ - Canceled - $ - - $ - Outstanding, end of period 1,615,000 $ 1.97 670,000 $ 1.93 Options exercisable, end of period 1,486,670 $ 1.98 13,334 $ 2.00 Options expected to vest, end of period 128,330 $ 1.81 656,666 $ 1.89 Weighted average fair value of options granted $ 2.19 $ 2.36

Capital Stock (Tables)

Capital Stock (Tables)	12 Months Ended
	Dec. 31, 2018
Equity [Abstract]
Schedule of fair value warrants assumptions	Measurement date Dividend yield 0% Expected volatility 97.90~119.33% Risk-free interest rate 1.47~1.60% Expected life (years) 2.71~2.92 Stock Price $ 0.25 Exercise Price $ 0.40
Schedule of common stock purchase warrants were outstanding	Warrants (1) Weighted Average Exercise Price Outstanding – December 31, 2016 502,000 $ 0.40 Granted 64,000 0.40 Forfeited/Canceled - - Exercised 512,000 (2) 0.40 Outstanding – December 31, 2017 54,000 0.40 Granted - - Forfeited/Canceled - - Exercised 2,000 (3) 0.40 Outstanding – December 31, 2018 52,000 $ 0.40 (1) Each two shares of common stock purchased under the private placement provides for one warrant to acquire an additional share of common stock together with the payment of $0.40. (2) During the year ended December 31, 2017, investors exercised warrants to purchase an aggregate of 512,000 shares of common stock and received 442,960 underlying shares for exercises on a cashless basis. (3) During the year ended December 31, 2018, investors exercised warrants to purchase an aggregate of 2,000 shares of common stock and received 1,715 shares for exercises on a cashless basis.

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Schedule of income tax expense (benefit)	December 31, 2018 December 31, 2017 Total current $ - $ - Total deferred - - $ - $ -
Schedule of reconciliation of the expected statutory federal income tax and state income tax provisions	December 31, 2018 December 31, 2017 Expected benefit at federal statutory rate $ 825,500 298,900 Non-deductible expenses (724,200 ) (198,900 ) Change in valuation allowance (101,300 ) (100,000 ) $ - $ -
Schedule of deferred income tax assets	December 31, 2018 December 31, 2017 Loss carryforwards $ 1,137,380 $ 333,880 Less – stock based compensation (933,600 ) (210,600 ) Less – derivative liabilities (2,480 ) (1,280 ) Change in tax effected rates - (22,000 ) Less - valuation allowance (201,300 ) (100,000 ) Total net deferred tax assets $ - $ -

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Level 1 [Member]
Liabilities
Derivative liabilities
Level 2 [Member]
Liabilities
Derivative liabilities
Level 3 [Member]
Liabilities
Derivative liabilities	$ 36,827	$ 31,090

Summary of Significant Accoun_5

Summary of Significant Accounting Policies (Details 1) - shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Potentially dilutive securities net loss per share	2,081,734	1,405,711
Warrant [Member]
Potentially dilutive securities net loss per share	52,000	54,000
Research Warrants at 3% of issued and outstanding shares [Member]
Potentially dilutive securities net loss per share	386,170	372,147
Convertible Notes [Member]
Potentially dilutive securities net loss per share	27,864	18,864
Series A Preferred shares [Member]
Potentially dilutive securities net loss per share	700	700
Stock options vested [Member]
Potentially dilutive securities net loss per share	1,486,670	13.334
Stock options not yet vested [Member]
Potentially dilutive securities net loss per share	128,330	656,666
Stock award not yet vested [Member]
Potentially dilutive securities net loss per share		290,000

Summary of Significant Accoun_6

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Accounting Policies [Abstract]
Research and development costs	$ 919,706	$ 1,179,777
Advertising or marketing costs	$ 56,879	$ 28,481
Research warrants issued and outstanding, percentage	3.00%

Convertible Note - Related Pa_3

Convertible Note - Related Party and Derivative Liabilities (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Notes to Financial Statements
Face value of certain convertible notes	$ 25,000	$ 25,000
Less: unamortized discount		(18,335)
Carrying value	$ 25,000	$ 6,665

Convertible Note - Related Pa_4

Convertible Note - Related Party and Derivative Liabilities (Details 1) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Notes to Financial Statements
Balance	$ 31,090
Derivative addition associated with convertible notes		25,000
Change in fair value	5,737	6,090
Balance	$ 36,827	$ 31,090

Convertible Note - Related Pa_5

Convertible Note - Related Party and Derivative Liabilities (Details 2)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Expected dividends	0.00%	0.00%
Risk free interest rate	2.60%
Minimum [Member]
Expected volatility	64.00%	110.00%
Expected term	8 months 1 day	8 months 1 day
Risk free interest rate		1.53%
Maximum [Member]
Expected volatility	65.00%	115.00%
Expected term	8 months 26 days	8 months 26 days
Risk free interest rate		1.65%
Commitment Date [Member]
Expected dividends	0.00%
Risk free interest rate	1.33%
Commitment Date [Member] | Minimum [Member]
Expected volatility	101.00%
Expected term	11 months 1 day
Commitment Date [Member] | Maximum [Member]
Expected volatility	103.00%
Expected term	1 year

Convertible Note - Related Pa_6

Convertible Note - Related Party and Derivative Liabilities (Details Narrative) - USD ($)	Sep. 09, 2018	Sep. 28, 2017	Sep. 27, 2017	Sep. 01, 2016	Dec. 31, 2018	Dec. 31, 2017
Convertible Note - Related Party and Derivative Liabilities (Textual)
Received proceeds totaling						$ 15,000
Amortization of discount					$ 18,335	$ 13,082
Cubesquare Llc [Member]
Convertible Note - Related Party and Derivative Liabilities (Textual)
Received proceeds totaling			$ 15,000	$ 10,000
Interest rate per annum			8.00%	8.00%
Conversion, description			Any portion of the principal and unpaid interest under the note is convertible at any time at the option of CubeSquare into shares of common stock of the Company at a conversion price equal to a 50% discount to the average of the five lowest trading prices during the previous twenty trading days prior to the date of the notice of conversion from CubeSquare.	(i) $0.0625 per share if the Company's shares are not trading on a public market and; (ii) in the event the Company's shares are listed for trading on a public market, the conversion price shall be equal to a 50% discount to the average of the five lowest trading prices during the previous twenty trading days prior to the date of the notice of conversion from the lender.
Maturity date				Sep. 1, 2017
Maturity date, description	Note 2 was amended to extend the maturity date until September 27, 2019.	Note 1 to extend the maturity date from September 1, 2017 to September 1, 2018 and on September 9, 2018, the Company further amended Note 1 to extend the maturity date to September 1, 2019, under the same terms and conditions.
Debt instument due date			Sep. 27, 2018
Cubesquare Llc [Member] | President [Member]
Convertible Note - Related Party and Derivative Liabilities (Textual)
Ownership percentage				25.00%

License and Research Funding _2

License and Research Funding Agreements (Details Narrative) - USD ($)	Mar. 06, 2018	Dec. 13, 2017	Dec. 14, 2016	Apr. 23, 2018	Dec. 31, 2018	Dec. 31, 2017
License and Research Funding Agreements (Textual)
Research and development costs					$ 919,706	$ 1,179,777
Shares issued for advisory services, value				75,000
Shares issued, value					$ 575,000	32,000
License and research funding agreement compensation paid, description	the Company entered into an additional service agreement with Ariel for the services of Professor Gadi Turgeman and his neurobiology research team in their lab pursuant to which the Company paid Ariel $20,580 on each of March 19, 2018 and August 22, 2018.				The Company paid Ariel (i) $17,250 on December 19, 2017 and an additional $17,250 on April 26, 2018. On April 12, 2018, the Services Agreement was amended to provide for the payment by the Company of an additional monthly fee, commencing March 2018, of up to 8,000 Israeli shekels as compensation for additional costs which the Company may request.
Ariel University [Member]
License and Research Funding Agreements (Textual)
Shares issued for advisory services, value		119,950
Shares issued, value		$ 335,860
Shares issued, percentage		1.00%
Licensing Agreements [Member]
License and Research Funding Agreements (Textual)
Total amount of fund for research during research period			$ 100,000
Warrant exercisable percentage			4.00%
Payments of completion of milestone events, description			Upon successful clinical FDA Phase II completion - $130,000; and Upon successful clinical FDA Phase III completion - $390,000
Research and development costs						1,179,777
Aforementioned funding amount						119,950
Stock based compensation						812,000
Payments of completion of milestone events due			6 months
Shares issued, value						$ 335,860

Commitments (Details Narrative)

Commitments (Details Narrative) - USD ($)

Jul. 12, 2018

Jun. 23, 2018

Apr. 12, 2018

Apr. 23, 2018

Jan. 23, 2018

Nov. 15, 2017

Dec. 31, 2018

Dec. 31, 2017

Aug. 22, 2018

Aug. 15, 2018

May 01, 2018

Apr. 26, 2018

Apr. 16, 2018

Mar. 19, 2018

Dec. 14, 2017

Commitments (Textual)

Compensation for the services provided

$ 17,250

$ 17,250

$ 17,250

Compensation cost

$ 33,781

$ 1,438

Advisors are granted the option

[1]

64,000

Service agreement payment, description

The Company of an additional monthly fee, commencing March 2018, of up to $2,130 (8,000 Israeli shekels) as compensation for additional costs which the Company may request.

Prepaid expenses

16,531

$ 15,812

Consulting fee

$ 5,000

Investor relations agreement, description

The Company gave notice of rescission of the agreement to such firm and requested the return of the consulting fee paid and the 75,000 shares of common stock. As a result, the Company has not recorded any fees for services rendered past June 23, 2018. A total of $10,000 representing April 2018 and May 2018 monthly consulting fees is reflected in the statement of operations and a total of $150,000, the fair market value of the issued shares, was expensed on issue.

The Company issued 75,000 shares of its common stock in respect of an investor relations services agreement which was rescinded on June 23, 2018 (Note 6(5)). The shares were valued at the fair market value on the date of issuance for a total of $150,000, or $2.00 per share.

Paid for additional fees

16,935

Issuance of common stock payable

75,000

Sponsored Research Agreement [Member]

Commitments (Textual)

Prepaid expenses

54,440

Prepaid expensed during period

27,220

Outstanding expenses

27,220

Sponsored research agreement, description

The Company entered into a one-year sponsored research agreement (the "Sponsored Research Agreement"), with the Trustees of Dartmouth College ("Dartmouth") pursuant to which the Company will support and fund the cost of research conducted by Dartmouth of mutual interest to the parties in accordance with the Agreement. Intellectual property invented or developed solely by a party shall be owned by such party and intellectual property jointly invented or developed shall be jointly owned. Dartmouth shall retain an irrevocable worldwide right to use intellectual property owned by it resulting from its research under the Agreement on a non-exclusive royalty-free basis for research and education purposes. The Company funded $36,293 on August 20, 2018 and will fund additional $18,147 by December 1, 2018 and $18,146 by June 1, 2019, respectively.

Service Agreement With Ariel [Member]

Commitments (Textual)

Compensation for the services provided

$ 20,580

$ 20,580

$ 17,250

Prepaid expenses

41,160

Prepaid expensed during period

34,300

Outstanding expenses

$ 6,860

Equity Option [Member]

Commitments (Textual)

Advisors are granted the option

10,000

20,000

Stock option and advisor granted

30,000

20,000

30,000

[1]

(1) Each two shares of common stock purchased under the private placement provides for one warrant to acquire an additional share of common stock together with the payment of $0.40.

Stock Plan (Details)

Stock Plan (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Number of shares vested in period	10,000	290,000
Fair market value per share	$ 2.80	$ 2.80
Stock based compensation recognized	$ 28,000	$ 812,000

Stock Plan (Details 1)

Stock Plan (Details 1) - Measurement Date [Member] - Equity Option [Member]	12 Months Ended
	Dec. 31, 2018$ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividend yield	0.00%
Exercise Price, Minimum	$ 0.40
Exercise Price, Maximum	$ 2
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	126.34%
Risk-free interest rate	2.68%
Expected life (years)	5 years
Stock Price	$ 2.80
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	114.69%
Risk-free interest rate	1.79%
Expected life (years)	3 years
Stock Price	$ 2

Stock Plan (Details 2)

Stock Plan (Details 2) - $ / shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Shares Outstanding, beginning of period	670,000
Shares, Granted	945,000	670,000
Shares, Exercised
Shares, Canceled
Shares Outstanding, end of period	1,615,000	670,000
Shares Options exercisable, end of period	1,486,670	13,334
Shares, Options expected to vest, end of period	128,330	656,666
Weighted Average Shares Exercise Price, Outstanding, beginning of period	$ 1.93
Weighted Average Shares Exercise Price, Granted	2	1.93
Weighted Average Shares Exercise Price, Exercised
Weighted Average Exercise Price, Canceled
Weighted Average Shares Exercise Price, Outstanding, end of period	1.97	1.93
Weighted Average Exercise Price, Options exercisable, end of period	1.98	2
Weighted Average Exercise Price, Options expected to vest, end of period	1.81	1.89
Weighted Average Exercise Price, Weighted average fair value of options granted	$ 2.19	$ 2.36

Stock Plan (Details Narrative)

Stock Plan (Details Narrative) - USD ($)	Dec. 10, 2018	Aug. 15, 2018	Dec. 14, 2017	Dec. 04, 2017	Dec. 14, 2016	Apr. 16, 2018	Nov. 15, 2017	Dec. 31, 2018	Dec. 31, 2017	Jan. 23, 2018
Stock Plan (Textual)
Total unrecognized compensation remaining to be recognized in future periods								$ 198,088
Board of Directors Chairman [Member]
Stock Plan (Textual)
Stock award					440,000
Receive common stock vest upon grant date					150,000
Vested shares			145,000		145,000
General and Administrative Expense [Member]
Stock Plan (Textual)
Stock-based compensation								592,019	$ 29,000
Equity Option [Member]
Stock Plan (Textual)
Reserved shares for issuance					10
Stock award										10,000
Description of services agreement		Under the 2016 Stock Option and Award Plan, the Board granted a Science Advisor an option to purchase an aggregate of 20,000 shares of common stock at an exercise price of $2.00 per share. The option vests as to 6,667 shares on each of August 15, 2018 and August 15, 2019 and as to 6,666 shares on August 15, 2020 and remains exercisable as to each such installment for three years from the date of vesting.				Under the 2016 Stock Option and Award Plan, the Board awarded a Science Advisor, the following three-year stock options: (i) an option to purchase 10,000 shares of common stock, exercisable on April 16, 2018 at an exercise price of $2.00 per share and (ii) an option to purchase 10,000 shares of common stock exercisable on April 16, 2019 at an exercise price of $2.00 per share, and (iii) an option to purchase 10,000 shares of common stock exercisable on April 16, 2020 at an exercise price of $2.00 per share, provided the advisor is still providing services to the Company. provided the advisor is still providing services to the Company.	Under the 2016 Stock Option and Award Plan, the Board awarded two of its Science Advisors the following three-year stock options: (i) an immediately exercisable option to purchase 6,667 shares of common stock at an exercise price of $2.00 per share, (ii) an option to purchase 6,667 shares of common stock exercisable on November 15, 2018 at an exercise price of $2.00 per share and (iii) an option to purchase 6,666 shares of common stock exercisable on November 15, 2019 at an exercise price of $2.00 per share, provided the advisors are still providing services to the Company.
Stock Option One [Member]
Stock Plan (Textual)
Description of services agreement							Under the 2016 Stock Option and Award Plan, the Board awarded a Science Advisor, the following three-year stock options: (i) an option to purchase 15,000 shares of common stock, exercisable on November 15, 2018 at an exercise price of $0.40 per share and (ii) an option to purchase 15,000 shares of common stock exercisable on November 15, 2019 at an exercise price of $0.40 per share, provided the advisor is still providing services to the Company.
Stock Options Granted To Officers [Member]
Stock Plan (Textual)
Total unrecognized compensation remaining to be recognized in future periods								0
Weighted average exercise price	$ 2			$ 2
Shares of common stock under certain vesting terms	5 years			5 years
Vest and exercisable date				Dec. 4, 2018
Granted an option to purchase shares of common stock	325,000			300,000
Stock Options Granted To Officers [Member] | General and Administrative Expense [Member]
Stock Plan (Textual)
Stock-based compensation								$ 2,673,011	$ 106,029
Stock Options Granted Employees [Member]
Stock Plan (Textual)
Description of services agreement	(i) an option to purchase 33,334 shares of common stock, exercisable on December 10, 2018 at an exercise price of $2.00 per share (ii) an option to purchase 33,333 shares of common stock exercisable on December 10, 2019 at an exercise price of $2.00 per share, and (iii) an option to purchase 33,333 shares of common stock exercisable on December 10, 2020 at an exercise price of $2.00 per share
Weighted average exercise price	$ 2
Shares of common stock under certain vesting terms	5 years
Granted an option to purchase shares of common stock	145,000
Stock-based compensation	$ 54,840
December Fourteen Two Zero One Eight [Member] | Board of Directors Chairman [Member]
Stock Plan (Textual)
Vested shares								145,000
Fourth Quarter [Member] | Stock Awards Not Yet Vested [Member]
Stock Plan (Textual)
Vested shares								290,000

Capital Stock (Details)

Capital Stock (Details) - Measurement Date [Member] - Warrant [Member]	12 Months Ended
	Dec. 31, 2018$ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividend yield	0.00%
Stock Price	$ 0.25
Exercise Price	$ 0.40
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	119.33%
Risk-free interest rate	1.60%
Expected life (years)	2 years 11 months 1 day
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	97.90%
Risk-free interest rate	1.47%
Expected life (years)	2 years 8 months 16 days

Capital Stock (Details 1)

Capital Stock (Details 1) - $ / shares		12 Months Ended
		Dec. 31, 2018		Dec. 31, 2017
Warrants
Outstanding - Beginning balance	[1]	54,000		502,000
Granted	[1]			64,000
Forfeited/Canceled
Exercised	[1]	2,000		512,000
Outstanding - Ending balance	[1]	52,000		54,000
Weighted Average Exercise Price
Outstanding - Beginning balance		$ 0.40		$ 0.40
Granted				0.40
Forfeited/Canceled
Exercised		0.40	[2]	0.40	[3]
Outstanding - Ending balance		$ 0.40		$ 0.40
[1]	(1) Each two shares of common stock purchased under the private placement provides for one warrant to acquire an additional share of common stock together with the payment of $0.40.
[2]	(3) During the year ended December 31, 2018, investors exercised warrants to purchase an aggregate of 2,000 shares of common stock and received 1,715 shares for exercises on a cashless basis.
[3]	(2) During the year ended December 31, 2017, investors exercised warrants to purchase an aggregate of 512,000 shares of common stock and received 442,960 underlying shares for exercises on a cashless basis.

Capital Stock (Details Narrativ

Capital Stock (Details Narrative) - USD ($)		Jun. 23, 2018	Feb. 06, 2018	Dec. 14, 2017	Dec. 13, 2017	Dec. 14, 2016	Apr. 23, 2018	Jan. 23, 2018	Dec. 31, 2018	Dec. 31, 2017
Capital Stock (Textual)
Common stock, shares authorized									100,000,000	100,000,000
Common stock, par value									$ 0.0001	$ 0.0001
Series A Preferred Shares, shares issued									2,000	2,000
Series A Preferred Shares, shares outstanding									2,000	2,000
Series A Preferred Shares, authorized									10,000	10,000
Series A Preferred Shares, par value									$ 0.001	$ 0.001
Shares issued for advisory services, value							75,000
Shares issued for advisory service									$ 575,000	$ 32,000
Cash paid									380,684
Purchase of common stock amount										$ 25,000
Subscriptions shares										128,000
Warrant, description			The Company received a warrant exercise notice in respect of 2,000 warrants from a subscriber and issued 1,715 shares of common stock on a cashless exercise basis as per the cashless exercise formula contained in the warrant.
Warrant exercise	[1]								2,000	512,000
Warrants received underlying shares for exercise on a cashless basis										442,960
Investor relations agreement, description		The Company gave notice of rescission of the agreement to such firm and requested the return of the consulting fee paid and the 75,000 shares of common stock. As a result, the Company has not recorded any fees for services rendered past June 23, 2018. A total of $10,000 representing April 2018 and May 2018 monthly consulting fees is reflected in the statement of operations and a total of $150,000, the fair market value of the issued shares, was expensed on issue.					The Company issued 75,000 shares of its common stock in respect of an investor relations services agreement which was rescinded on June 23, 2018 (Note 6(5)). The shares were valued at the fair market value on the date of issuance for a total of $150,000, or $2.00 per share.
Additional share of common stock per share									$ 0.40
Warrant [Member]
Capital Stock (Textual)
Warrant exercise	[2]									512,000
Series A Preferred Stock [Member]
Capital Stock (Textual)
Preferred stock, conversion basis, description									The Series A Preferred Stock is redeemable at the option of the Company at any time, in whole or in part, upon 10 trading days prior notice, at a price of $1.00 per share plus 4% per annum from the date of issuance (the "Stated Value"). The holders of the Series A Preferred Stock are entitled to a liquidation preference equal to the Stated Value, prior to the holders of other preferred stock or common stock. The holders of the Series A Preferred Stock have the right to convert such stock into common stock at a conversion rate equal to the Stated Value as of the conversion date divided by the average closing price of the common stock for the five previous trading days. The Company is required to reserve sufficient number of shares for the conversion of the Series A Preferred Stock. The holders of Class A Preferred Stock shall vote together as a single class with the holders of the Company's common stock and the holders of any other class or series of shares entitled to vote with the common stock, with the holders of Class A Preferred Stock being entitled to 66 2/3% of the total votes on all such matters, regardless of the actual number of shares of Class A Preferred Stock then outstanding.
Private Placement [Member]
Capital Stock (Textual)
Sale and issuance of common stock								10,000
Total proceeds of subscriptions amount								$ 28,000		$ 32,000
Investor relations agreement, description								The Company issued 10,000 shares for advisory services (Note 6(4)). The shares were valued at fair market value on the date of issuance for a total of $28,000 or $2.80 per share.
Board of Directors Chairman [Member]
Capital Stock (Textual)
Stock award						440,000
Vested shares				145,000		145,000
Receive common stock vest upon grant date						150,000
Two Scientific Advistors [Member]
Capital Stock (Textual)
Share issued for agreement				290,000
Conversion value				$ 812,000
Conversion of stock par value				$ 2.80
Ariel University [Member]
Capital Stock (Textual)
Shares issued for advisory services, value					119,950
Shares issued for advisory service					$ 335,860
Investors [Member]
Capital Stock (Textual)
Warrant exercise									2,000
Warrants received underlying shares for exercise on a cashless basis									1,715
License Agreement Terms [Member]
Capital Stock (Textual)
Share issued for agreement					119,950
Conversion value					$ 335,860
Conversion of stock par value					$ 2.80
[1]	(1) Each two shares of common stock purchased under the private placement provides for one warrant to acquire an additional share of common stock together with the payment of $0.40.
[2]	Each two shares of common stock purchased under the private placement provides for one warrant to acquire an additional share of common stock together with the payment of $0.40.

Income Taxes (Details)

Income Taxes (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Total current
Total deferred
Total

Income Taxes (Details 1)

Income Taxes (Details 1) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Expected benefit at federal statutory rate	$ 825,000	$ 298,900
Non-deductible expenses	(724,200)	(198,900)
Change in valuation allowance	(101,300)	(100,000)
Total

Income Taxes (Details 2)

Income Taxes (Details 2) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Loss carryforwards	$ 1,137,380	$ 333,880
Less – stock based compensation	(933,600)	(210,600)
Less – derivative liabilities	(2,480)	(1,280)
Change in tax effected rates		(22,000)
Less - valuation allowance	(201,300)	(100,000)
Total net deferred tax assets

Income Taxes (Details Narrative

Income Taxes (Details Narrative)	12 Months Ended
	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Statutory income tax rate	21.00%

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - Subsequent Event [Member] - USD ($)	1 Months Ended
	Feb. 25, 2019	Jan. 28, 2019
Pavel Hilman [Member]
Number of shares issued, shares		30,000
Investors [Member]
Number of shares issued, shares	40,000
Number of shares issued, value	$ 40,000